NASDAQ:COYA Coya Therapeutics Q1 2025 Earnings Report $5.08 -0.10 (-1.93%) Closing price 04:00 PM EasternExtended Trading$5.07 -0.01 (-0.20%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Coya Therapeutics EPS ResultsActual EPS-$0.44Consensus EPS -$0.44Beat/MissMet ExpectationsOne Year Ago EPSN/ACoya Therapeutics Revenue ResultsActual Revenue$257.88 millionExpected Revenue$2.63 millionBeat/MissBeat by +$255.25 millionYoY Revenue GrowthN/ACoya Therapeutics Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateTuesday, May 13, 2025Conference Call Time8:00AM ETUpcoming EarningsCoya Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Coya Therapeutics Earnings HeadlinesAnalyzing Coya Therapeutics (NASDAQ:COYA) and Zealand Pharma A/S (OTCMKTS:ZLDPF)September 21, 2026 | americanbankingnews.comBTIG Research Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA)September 17, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 25 at 1:00 AM | Profits Run (Ad)Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALSSeptember 15, 2026 | finance.yahoo.comCoya Therapeutics Advances COYA 302 ALS Phase 2/3 TrialSeptember 15, 2026 | tipranks.comCoya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALSSeptember 15, 2026 | businesswire.comSee More Coya Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Coya Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coya Therapeutics and other key companies, straight to your email. Email Address About Coya TherapeuticsCoya Therapeutics (NASDAQ:COYA) is a clinical-stage biotechnology company focused on developing therapies designed to enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune responses and may play a role in limiting inflammation associated with neurodegenerative and autoimmune diseases. The company’s pipeline includes investigational Treg-based therapies, including COYA 301, an autologous Treg therapy being evaluated for potential use in conditions such as amyotrophic lateral sclerosis (ALS). Coya is also developing combination approaches intended to improve Treg activity and persistence, including programs involving low-dose interleukin-2. Its candidates remain experimental and are subject to clinical and regulatory evaluation. Headquartered in Houston, Texas, Coya Therapeutics became a publicly traded company through a business combination with Nicoya Healthcare in 2023. The company’s development strategy is centered on advancing its proprietary Treg-focused platform for diseases in which chronic inflammation and impaired immune regulation may contribute to disease progression.View Coya Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
